NEWS ARCHIVE
Latest news
- CiMaas wishes our partners a very happy 2026 and we are looking forward to successful collaborations in achieving our common goals.
- CiMaas obtained another grant from LIOF for validation of its feeder cell technology
- CiMaas moves into new facility
- CiMaas cell therapy programs for treatment of patients with cancer gets a new boost
- CiMaas and CYTEA BIO are pleased to announce their collaboration on Natural Killer cells
- CiMaas receives EMA qualification for NK cell product
- EU grants Seal of Excellence to CiMaas
- CiMaas improved large scale NK cell expansion using its newly developed feeder cell technology
- Combotope Therapeutics and CiMaas Announce Oncology Research and License Option Agreement
- CiMaas filed patent application on feeder cell preparation in support of its NK cell therapy program
- CiMaas has created a master cell and working cell bank of its feeder cell line to expand NK cells with maximum proliferation
- CiMaas receives a LIOF grant to optimize feeder cells preparation facilitating expansion of Natural Killer cells
- CiMaas receives exclusive option for the use of high affinity antibody structures in immune cells, including CAR-NK and CAR-T cells
- Dean Lee joins scientific advisory board of CiMaas
- CiMaas to present at Biotech Showcase 2023
- CiMaas reaches next milestone in NK cell expansion and function
- CiMaas receives Manufacturing Authorisation
- CiMaas and consortium receive Health Holland subsidy
- CiMaas receives RVO innovation credit for DC vaccine clinical trial
- Jolanda de Vries joins scientific advisory board of CiMaas